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ABSTRACT
Aptamers offer advantages over other oligonucle-
otide-based approaches that artificially interfere with
target gene function due to their ability to bind
protein products of these genes with high affinity
and specificity. However, RNA aptamers are limited
in their ability to target intracellular proteins since
even nuclease-resistant aptamers do not efficiently
enter the intracellular compartments. Moreover,
attempts at expressing RNA aptamers within mam-
malian cells through vector-based approaches have
been hampered by the presence of additional flank-
ing sequences in expressed RNA aptamers, which
may alter their functional conformation. In this
report, we successfully expressed a ‘pure’ RNA
aptamer specific for NF-kB p50 protein (A-p50)
utilizing an adenoviral vector employing the H1
RNA polymerase III promoter. Binding of the
expressed aptamer to its target and subsequent
inhibition of NF-kB mediated intracellular events
were demonstrated in human lung adenocarcinoma
cells (A549), murine mammary carcinoma cells (4T1)
as well as a human tumor xenograft model. This
success highlights the promise of RNA aptamers to
effectively target intracellular proteins for in vitro
discovery and in vivo applications.
INTRODUCTION
Over the last 20 years, different strategies have been
developed to manipulate gene expression and/or function
with oligonucleotides. These include antisense oligonuc-
leotides, ribozymes and, more recently, small interfering
RNA (1). Although these approaches in principle allow the
rational design of regulatory sequences, they are poorly adap-
ted to target proteins (2,3). The idea of using single-stranded
nucleic acids (DNA and RNA aptamers) to target protein
molecules is based on the ability of short sequences
(20mers to 80mers) to fold into unique 3D conformations
that enable them to bind targeted proteins with high afﬁnity
and speciﬁcity (4–6). RNA aptamers have been expressed
successfully inside eukaryotic cells, such as yeast and multi-
cellular organisms, and have been shown to have inhibitory
effects on their targeted proteins in the cellular environment
(7–9). However, simple and reliable methods for expressing
RNA aptamer that target intracellular proteins in mammalian
cells are currently lacking. Attempts at expressing RNA apta-
mers through vector-based approaches have been hampered
by the presence of ﬂanking sequences in expressed RNA
aptamers which can inhibit their ability to fold into functional
conformations, thus rendering the aptamer inert (10–12).
Therefore, it will be critical to develop vectors that will
allow expression of ‘pure’ RNA aptamer sequences following
delivery into targeted cells. Although there are potential gene
therapy implications of such an expression system, the greater
beneﬁts would be realized in exploring the biology of intra-
cellular protein pathways and in identifying and conﬁrming
the relevancy of candidate proteins for targeted therapeutics.
Constitutively high levels of nuclear NF-kB activity have
been described in many types of cancer cells and abrogation
of constitutive NF-kB activity results in apoptosis of treated
tumor cells (13,14). A 31 nt RNA aptamer was shown previ-
ously to target the p50 subunit of NF-kB in yeast (15,16).
However, effects of the RNA aptamer on NF-kB transcrip-
tional activity in mammalian cells have not yet been demon-
strated. In this study, we successfully produced an adenoviral
vector to express the ‘pure’ RNA aptamer of NF-kBp 5 0
protein (termed A-p50). The expressed A-p50 effectively
inhibits NF-kB transactivation and induces apoptosis in
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mammary carcinoma cells (4T1) and also delays tumor
growth in a human tumor xenograft model.
MATERIALS AND METHODS
Cell culture
The following cell lines were used in this study: (i) HEK 293,
an adenovirus E1 gene-transduced human embryonic kidney
cell line for adenovirus packaging and expansion; (ii) A549,
a human lung adenocarcinoma cell line obtained from
American Type Culture Collection (Manassas, Virginia);
and (iii) 4T1 mouse mammary carcinoma cells were obtained
from Dr Fred Miller’s laboratory (Michigan Cancer Founda-
tion, Detroit, MI). These cell lines were grown in DMEM
(Invitrogen Inc., Carlsbad, CA) with 10% fetal bovine serum,
100 U/ml penicillin and 100 mg/ml streptomycin at 37 C
in 5% CO2.
A-p50 RNA aptamer expression cassette design
A 31 nt A-p50 minigene sequence (ATCTTGAAACTGTT-
TTAAGGTTGGCCGATC) was synthesized for transcription
of A-p50 aptamer. Two complementary oligonucleotides
were synthesized and annealed to yield the 31 nt A-p50
expression minigene. A tract of six thymidines was included
at the 30 end to terminate RNA pol III transcription. BamHI-
and HindIII-compatible overhangs were introduced at each
end to facilitate ligation into the pSilencer-3.0 vector. An
H1 promoter is upstream of the BamHI site to initiate trans-
cription precisely at the +1 position. The resultant plasmid is
the pSilencer-A-p50 (Figure 1A). As a negative control, a
47 nt small sequence (TTCTCCGAACGTGTCACG-
TTTCAAGAGAACGTGACACGTTCGGAGAA) with no
known target (siNT) in the human genome was cloned
into the adenoviral vector in place of the A-p50 minigene
(17,18).
Plasmid construction and adenovirus production
The AdEasy system (Stratagene, La Jolla, CA) was used to
generate recombinant adenoviruses Ad-A-p50 and Ad-siNT.
The A-p50-encoding gene expression cassette (eA-p50),
including the H1 promoter, the A-p50 minigene sequence
and six terminal thymidines, was excised by EcoRI/HindIII
from pSilencer-A-p50 and subcloned into the EcoRV/HindIII
sites of pAdTrack after blunting the EcoRI site (Figure 1B).
The resultant plasmid, pAdTrack-A-p50, was packaged into
recombinant adenovirus, according to the manufacturer’s pro-
tocol. Brieﬂy, the pAdtrack-A-p50 plasmid was linearized
with PmeI and recombined with pAdeasy-1 plasmid in
recA+ BJ5183 Escherichia coli. The recombined pAdeasy-
A-p50 plasmid was linearized with PacI and then transfected
into the 293 cells to obtain recombinant adenovirus,
Ad-A-p50. Large-scale virus preparation was performed
according to established protocols. The control virus,
Ad-siNT, was produced in a similar manner. Both viruses
express enhanced green ﬂuorescent protein (EGFP) under
the direction of a CMV promoter, which allows assessment
of viral infection.
Northern blot analysis
Total RNA was extracted from Ad-siNT- or Ad-A-p50-
infected A549 cells (10 MOI, 24 h). Total RNA (10 mg)
was loaded onto a 2% denaturing formaldehyde gel and trans-
ferred to a nylon membrane. Prehybridization and hybridiza-
tion were performed with the ExpressHyb buffer (Invitrogen)
at 68 C. The membrane was rinsed per the manufacturer’s
instructions (Invitrogen) and exposed to ﬁlm for signal detec-
tion. For A-p50 RNA detection, the antisense oligonucleotide
of A-p50 (50-GATCGGCCAACCTTAAAACAGTTTCAAG-
ATC-30) was
32P-labeled by using [g-
32P]ATP and T4 poly-
nucleotide kinase. The
32P-end labeled oligonucleotide
probe was used directly for hybridization.
Figure 1. Strategy for production of A-p50 aptamer expression vectors. (A)
Construction of A-p50 aptamer expression cassette. Two complementary
oligonucleotides containing the 31 nt A-p50 minigene (italic) and six
thymidines to terminate transcription were ligated into the expression vector
pSilencer-3.0 downstream of a human H1 gene-based RNA polymerase III
promoter. Upon transcription, two additional uridines are present at the A-p50
30 end. The predicted secondary structure suggests that these uridines have a
negligible effect on the A-p50 conformation. A 12 nt antidote complementary
to a portion of the A-p50 RNA aptamer sequence was designed and predicted
to inactivate A-p50 by blocking its secondary structure formation. (B)
Production of A-p50 expressing adenovirus. The expression cassette, eA-p50,
was excised from pSilencer-A-p50 and inserted into the pAdTrack vector to
produce pAdTrack-A-p50. After recombination with the virus backbone,
pAdEasy-1, in recA+ BJ5183 E.coli, the recombinant adenoviral vector was
linearized with PacI and transfected into HEK293 cells to allow large-scale
virus production.
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western blot analysis
A549 cells were infected with Ad-A-p50 or Ad-siNT
(10 MOI, 24 h). Nuclear extracts were obtained by incubating
cells with hypotonic buffer A [20 mM HEPES, pH 7.0,
10 mM KCl, 1 mM MgCl2, 10% glycerol, 0.5 mM DTT
and 0.25 mM phenylmethylsulfonyl ﬂuoride (PMSF)] for
10 min on ice. The lysates were centrifuged at 200 g for
10 min and the pellet was then washed three times with buffer
A. To extract nuclear proteins for western blot analysis, 50 ml
buffer A containing 300 mM NaCl and 0.1% NP-40 was
ﬁnally applied to the pellet. For total cell protein extraction,
cells were homogenized in protein inhibitor containing buffer
(5 mM Tris–HCl, pH 7.4 and 2 mM EDTA) and sonicated for
10–15 s. After centrifuge to remove large cell debris, super-
natants were harvested and concentrations were determined
by the DC protein assay (Bio-Rad Laboratories Inc., Hercu-
les, CA). Proteins were electrophoresed on a 4–15% SDS–
PAGE gel and then transferred to a nitrocellulose membrane.
After blocking, the membrane was incubated with the prim-
ary antibody for 2 h, washed with phosphate-buffered saline
(PBS)/0.1% Tween-20 three times and then incubated with
horseradish peroxidase-conjugated secondary antibody
(IgG). After washing, the signal was visualized by use of
the ECL kit (Amersham, Arlington Heights, IL). The primary
antibody to Bcl-XL was purchased from BD Science (Palo
Alto, CA), to NF-kB p50 was from Upstate (Lake Placid,
NY), and to cleaved caspase-3 was from Cell Signaling
Technology (Beverly, MA).
Intracellular binding assay
Dishes (10 cm) of Ad-A-p50- or Ad-siNT-infected A549 cells
(5 MOI for 24 h) were treated with 1% formaldehyde for
10 min at 37 C to crosslink oligonucleotides and associated
proteins. Cells were then homogenized by incubating cells
with 200 ml lysis buffer (20 mM HEPES, 100 mM NaCl,
1.5 mM MgCl2, 0.5% NP-40, 10 mg/ml aprotinin, 0.5 mM
PMSF and 10% v/v RNase inhibitor) for 30 min, followed
by brief sonication on ice. Co-immunoprecipitation (IP) of
A-p50 RNA with NF-kB p50 was performed by incubating
100 ml of protein extracts with 5 mg rabbit anti-NF-kB
(p50) antibody or non-speciﬁc rabbit IgG as a negative con-
trol overnight at 4 C. Protein A–agarose slurry (Upstate,
Waltham, MA) was added for 2 h at 4 C. The beads were
spun at 3000 g for 4 min at 4 C and the pellet was washed
three times with 1 ml ice-cold lysis buffer. The ﬁnal pellet
was resuspended in 500 ml of solution D (20 mM HEPES,
20% glycerol, 0.1 M KCl, 0.2 mM EDTA and 0.5 mM
DTT) and incubated with proteinase K (40 mg/ml) for 1 h
at 42 C. Protein-associated RNA was isolated by phenol-
chloroform extraction and isopropanol precipitation and
reverse-transcribed with an A-p50 reverse primer, A-p50R
(50-GTCCTAAGGTAGCAGAGATCGGCCAACCT-30). The
presence of A-p50 RNA was veriﬁed by PCR with an
A-p50 forward primer, A-p50F (50-GGATAACAGGGTAAT-
GATCTTGAAACTGTT-30) together with A-p50R. Because
the 31 nt A-p50 is so small and is difﬁcult to visualize on a
gel, these primers were designed to contain 15 additional
bases (italics), which do not match any known mammalian
gene sequences. A two-step PCR was performed (94 C,
30 s; 50 C, 40 s) for 30 cycles to amplify a 62 bp A-p50
band. PCR products were veriﬁed by sequencing.
NF-kB-driven GFP reporter assay
In order to assay the function of NF-kB, the NF-kB cis-
reporting plasmid (pNF-kB-hrGFP) with a humanized green
ﬂuorescent protein (hrGFP) reporter was utilized (Strata-
gene). In this system, hrGFP gene is driven by a synthetic
promoter containing NF-kB binding site repeats. A549 cells
(1 · 10
6) were co-transfected with a total of 4 mg DNA, con-
sisting of 1 mg pNF-kB-hrGFP and 3 mg of either pSilencer
3.0 empty plasmid or pSilencer-A-p50. pSilencer 3.0 vector
alone was used as a negative control for hrGFP expression.
The electro-transfection approach was performed accord-
ing to the manufacturer’s recommendations (Bio-Rad, Phil-
adelphia, PA). To ensure equal transfection efﬁcacy, the
transfection procedure was strictly controlled. After a 36 h
incubation, hrGFP expression was visualized by ﬂuorescence
microscopy.
Cell analysis by flow cytometry
GFP detection by ﬂow cytometry has been described in detail
previously (19). A549 cells (1 · 10
6) were electro-transfected
as described above. The transfected cells were allowed to
recover and express hrGFP for 36 h, then cells were pelleted,
washed and ﬁxed with PBS-1% formaldehyde. A sample of
5 · 10
5 cells was analyzed using a BD Bioscience FACS
Calibur. Data were analyzed and presented using Cell
Quest Software. The percentage of hrGFP-expressing cells
was calculated by dividing the number of green-ﬂuorescent
cells observed by the total number of cells counted.
MTT assay
The MTT assay (Sigma, St Louis, MO) examines the activity
of metabolic enzymes in the mitochondria of live cells. Cells
were grown to 70% conﬂuence in 96-well plates and infected
with Ad-A-p50 or Ad-siNT (MOI of 10) for 24 h. The MTT
assay was carried out by an established protocol (18). The
values were normalized against non-infected cells and results
were analyzed using Student’s t-test.
Hoechst 33342 staining for apoptotic morphology
Cells were grown to 70% conﬂuence in 12-well plates, infec-
ted with Ad-A-p50 or Ad-siNT (10 MOI) for 24 h, and then
the cells were ﬁxed in methanol:acetic acid (3:1) for 5 min at
4 C and washed three times with water. Subsequently, the
cells were stained with Hoechst 33342 (5 mg/ml; Calbiochem,
La Jolla, CA) for 10 min at room temperature. The cells were
then washed three times with water, and apoptotic nuclei
were visualized by ﬂuorescence microscopy.
Protection analysis by antidotes
A 12 nt antidote complementary to a portion of the A-p50
RNA aptamer was designed (50-mAmGmUmUmUmCm-
AmAmGmAmUmC-Cy5-30). All of the 12 nt were methyl-
ated to protect the antidote from RNase degradation.
The 30-terminal Cy-5 modiﬁcation allows assessment of
transfection efﬁcacy. As a negative control (siNT), we
adapted the no-target sequence used for Ad-siNT in
the same manner with methyl and Cy-5 modiﬁcations
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AmCmGmT-Cy5-30). A549 cells were grown to 30–40%
conﬂuence in 12-well plates, infected with Ad-siNT or
Ad-A-p50 (10 MOI) for 1 h, then transfected with antidote
(150 pmol) or siNT control RNA (120 pmol) by using
lipofectamine-based approach and continually cultured for
23 h. Under ﬂuorescence microscopy, the efﬁcacy of antidote
and control siNT transfection was shown by Cy-5 (red) visu-
alization, and the efﬁcacy of Ad-siNT and Ad-A-p50 infec-
tion was shown by GFP expression (green). The apoptotic
cell nuclei were visualized by Hoechst 33342 (blue) staining.
Quantitative analysis of the extent of apoptosis in different
cell populations was conducted in 12 random ﬁelds of 3 inde-
pendent wells with the same treatment. Student’s t-test was
used to assess signiﬁcance.
Tumor growth delay studies
For in vivo analysis of tumor growth, 1 · 10
6 A549 tumor
cells in 50 ml of PBS were injected subcutaneously into the
ﬂanks of Balb/C nude mice. When tumors grew to sizes of
4–5 mm in diameter, adenoviruses (1 · 10
8 plaque-forming
units in 25 ml) were injected into the tumors (day1 in Figure
4A). Adenoviruses were injected every 48 h for 2 weeks, and
tumor growth was measured every 48 h. Growth curves were
plotted as the mean of tumor volume relative to that on the
ﬁrst day of injection ± SEM. Each treatment group consisted
of six to seven animals. The following formula was used to
calculate tumor volume: V ¼ (1/2)W
2 · L (W, the shortest
dimension and L, the longest dimension) (18). The results
were analyzed by one-way repeated-measures ANOVA and
the interactive term was evaluated by Bonferroni corrected
pair-wise comparisons.
Immunohistochemistry
Immunohistochemistry was performed using 10–12 mm serial
sections of frozen tissue. Sections were ﬁxed in ice-cold acet-
one for 10 min. After endogenous peroxidase activity was
quenched with 3% hydrogen peroxide for 15 min, tumor
sections were blocked with 10% donkey serum for 15 min.
Sections were incubated in anti-rabbit primary antibodies
against Bcl-XL (1:800; BD-Pharmingen, USA), activated
caspase-3 (1:100; Cell Signaling Technology) and Ki67
(1:2000; Vector-Labs, USA) for 1 h at room temperature,
respectively. After washing in PBS, biotinylated donkey
anti-rabbit antibody (Jackson Immunoresearch, PA) was
applied for 30 min at room temperature, followed by applica-
tion of an avidin–biotin complex (Vectastain ABC kit; Vector
Labs, Inc., Burlingame). Staining was visualized with the
Nova Red kit (Vector Labs, Inc.), and slides were counter-
stained with hematoxylin. Omission of the primary antibody
served as negative control. Staining was evaluated at lower
(·100) and higher (·400) magniﬁcations of four to ﬁve
randomly chosen ﬁelds.
RESULTS AND DISCUSSION
In an attempt to achieve high level of expression of RNA
aptamers that maintain their afﬁnity for the targeted protein,
we adopted the pSilencer-3.0 vector (Ambion Inc., Austin,
TX) that employs H1 RNA polymerase III promoter for
high level of small RNA expression (20). The advantage of
this vector is that RNA transcription starts accurately at the
initial base of inserted sequences and terminates with the
addition of two uridines (U) at the 30 end. Based on RNA
structure predictions, the additional uridines should have min-
imal effect on aptamer folding (Figure 1A). This approach
also avoids non-speciﬁc effects that might be caused by tran-
scription of additional regions of vector sequence. To our
knowledge, this approach has not been used previously to
express RNA aptamers intracellularly.
We generated a recombinant adenovirus, Ad-A-p50
(Figure 1B) to deliver our aptamer, A-p50 consisting of
31 nt of optimized sequence (16). A potential advantage of
aptamers as therapeutic tools, which was demonstrated
recently by Rusconi et al. (21), is that complementary
sequences can be designed and used as ‘antidotes’, which
will bind and neutralize the aptamers activity. As such, we
designed a 12 nt antidote of A-p50 aptamer that is predicted
to inhibit A-p50 ability to fold into its functional conforma-
tion (Figure 1A). As a negative control, we replaced the
31 nt A-p50 sequence with a non-targeting small interfering
RNA (Ambion Inc.) to produce Ad-siNT. This small RNA
is predicted to fold into a hairpin loop, but importantly it
has been shown previously to exhibit no biological effects
on cell viability (17,18).
To determine whether the resulting adenoviral vector Ad-
A-p50 could express the A-p50 RNA aptamer, total RNA
from Ad-A-p50- or Ad-siNT-infected human lung adenocar-
cinoma A549 cells was subjected to northern blot analysis. A
low molecular weight band ( 33 nt) corresponding to the
size of the A-p50 RNA aptamer (plus two end uridines)
was detected only in RNA from Ad-A-p50-infected cells,
indicating that this adenovirus expressed the inserted
sequence (Figure 2A). An additional high molecular weight
band was also detected, which corresponded to the size of
viral genome DNA that was not effectively excluded in our
RNA isolation process. These data demonstrate that the modi-
ﬁed adenovirus used here can serve as an efﬁcient vector to
transduce RNA aptamers.
To verify the binding between A-p50 and NF-kB, RT–PCR
was used to amplify the A-p50 aptamer present in NF-kB
immunoprecipitates from infected A549 cells, which was
then visualized by agarose gel electrophoresis (Figure 2B).
A band consistent with A-p50 was ampliﬁed only when cell
lysates were immunoprecipitated with anti-NF-kB and not
with a non-speciﬁc rabbit IgG. This band was sequenced
and veriﬁed to contain the ampliﬁed A-p50 sequence. Con-
sistent with the previous reports (13,14,22), nuclear NF-kB
p50 expression was readily detectable in A549 cells
(Figure 2C and D). Interestingly, infection of A549 cells
with Ad-A-p50 virus resulted in an  2.6-fold reduction in
nuclear localized p50 (Figure 2C), but had no effect on
total cellular NF-kB p50 expression (Figure 2D). NF-kB
exists in the cytoplasm in an inactive state, where it is
bound to the inhibitor protein IkB, which inhibits NF-kB
translocation to the cell nucleus. Upon activation, NF-kB
translocates to the nucleus where it inﬂuences gene trans-
cription (23). However, IkBa expressed in the nuclear
compartment abrogates NF-kB/DNA interactions and pro-
motes the export of NF-kB back to the cytoplasm (24).
Thus, we speculated that the Ad-A-p50-induced reduction
3580 Nucleic Acids Research, 2006, Vol. 34, No. 12in nuclear NF-kB expression was due to A-p50 ability to
block NF-kB binding to DNA, resulting in increase of
IkBa-mediated export to the cytoplasm. These data
demonstrate that A-p50 interacts speciﬁcally with p50
protein in mammalian cells following adenoviral delivery
and expression.
We next used a NF-kB reporter system (Stratagene) to
examine whether interaction with A-p50 affects NF-kB’s
transcriptional activity. Upon binding NF-kB, GFP expres-
sion is induced and can be visualized by ﬂuorescence micro-
scopy. Because Ad-A-p50 also expresses GFP, we tested
effects of A-p50 on NF-kB-mediated transcription following
Figure 2. Expressed A-p50 exhibits biological activity in A549 cells. (A) Northern blot analysis of A-p50 expression. An expressed A-p50 band (lower panel)
and a viral genomic DNA band (upper panel) are visualized only in Ad-A-p50-infected A549 cells (Ad-A-p50). The size of the lower band was determined by
acrylamide gel electrophoresis relative to a 10 nt RNA ladder (Ambion). (B) Intracellular binding of A-p50 to NF-kB p50 protein. RT–PCR confirms the
presence of A-p50 aptamer in anti-NF-kB p50 immunoprecipitates from Ad-A-p50-infected A549 cells. M, 50 bp DNA ladder. (C) Western blot analysis of
NF-kB p50 protein in nuclear fractions. Ad-A-p50-infected A549 cells show a decrease in nuclear NF-kB p50 expression (Ad-A-p50) compared with Ad-siNT-
infected A549 cells. Expression of a-tubulin was used as a protein loading control. (D) Western blot analysis of NF-kB p50 protein in whole cell lysates. Ad-A-
p50-infected A549 cells show no changes in total NF-kB p50 protein level compared to Ad-siNT-infected A549 cells. (E) Inhibition of NF-kB-mediated
transcriptional activity by A-p50 in cells. Upper panel: By fluorescence microscopy, the pNF-kB-hrGFP-transfected A549 cells show high GFP protein
expression (middle panel) compared to none in the empty plasmid-transfected cells (left panel). Co-transfection of A-p50 expression plasmid and pNF-kB-hrGFP
results in a decrease in hrGFP expression (right panel). Lower panel: quantitative analysis of GFP expression by flow cytometry. Co-transfection of
A-p50 expression vector with pNF-kB-hrGFP results in about a 70% decrease in GFP expression (right panel) compared to co-transfection of pSilencer3.0 and
pNF-kB-hrGFP (middle panel). As a control, transfection of empty plasmid alone showed no GFP expression (left panel).
Nucleic Acids Research, 2006, Vol. 34, No. 12 3581plasmid transfection with pSilencer-A-p50. Transfection of a
plasmid encoding the NF-kB-hrGFP reporter into A549 cells
resulted in readily detectable GFP expression as a result of
endogenous NF-kB activity. Notably, co-transfection of
pSilencer-A-p50 along with the NF-kB-hrGFP reporter plas-
mid resulted in marked attenuation of GFP expression
(Figure 2E, upper panels). Using quantitative ﬂow cytometry,
co-transfection of pSilencer-A-p50 induced an  70% inhibi-
tion in NF-kB-mediated GFP expression (Figure 2E, lower
panels). These data clearly illustrate that A-p50 aptamer
expression in cells abolishes binding of NF-kB to its target
DNA and inhibits NF-kB-mediated gene transcription.
Several studies have shown that activated NF-kB promotes
cell survival while suppression of NF-kB activity abrogates
this process (25). To investigate whether inhibition of
NF-kB DNA-binding activity could result in cell death
in vitro, the MTT assay, Hoechst 33342 staining of apoptotic
nuclei and western blotting of cleaved caspase-3 were used to
Figure 3. A-p50 affects tumor cell survival in vitro through inhibition of NF-kB-mediated transcriptional activation. (A) MTT assay of cell viability. Ad-A-p50-
infected A549 cells show a significant decrease in cell viability (Ad-A-p50) compared to Ad-siNT-infected cells, n ¼ 3–5 per group, **P ¼ 0.0001. (B) Hoechst
33342 staining of apoptotic nuclei. Ad-A-p50-infected A549 cells (Ad-A-p50) show increased numbers of apoptotic nuclei compared with Ad-siNT-infected
cells. (C) Western blot analysis of cleaved, active caspase-3. Ad-A-p50 infection increases activated caspase-3 levels in A549 cells. (D) Western blot analysis of
Bcl-XL expression. Ad-A-p50 infection results in downregulation of Bcl-XL expression. (E) Analysis of antidote-mediated protection in A549 cells. Upper panel
shows the transfection efficacy of antidote and control siNT small RNA (Cy-5). Middle panel shows the infection efficiency of Ad-siNT and Ad-A-p50 (GFP).
Lower panel shows Hoechst 33342 staining of apoptotic nuclei. The increased apoptotic nuclei in Ad-A-p50-infected A549 cells (Ad-A-p50) were partly reversed
by the antidote. (F) Quantification of apoptosis in (E). Bars, mean ± SD of data from 12 fields in 3 independent wells with the same treatment. **P ¼ 0.0004
versus Ad-siNT + antidote control group; *P ¼ 0.042 versus Ad-A-p50 + siNT group. (G) MTT assay of cell viability. Ad-A-p50-infected 4T1 cells show a
significant decrease in cell viability (Ad-A-p50), n ¼ 3–5 per group, **P ¼ 0.0001. (H) Hoechst 33342 staining of apoptotic nuclei. Ad-A-p50-infected 4T1 cells
(Ad-A-p50) show increased numbers of apoptotic nuclei compared to Ad-siNT-infected cells.
3582 Nucleic Acids Research, 2006, Vol. 34, No. 12evaluate cell viability and apoptosis. MTT assay showed a
signiﬁcant decrease in cell viability in Ad-A-p50-infected
A549 cells (65.3%) compared with Ad-siNT controls (P <
0.001) (Figure 3A). Hoechst 33342 staining demonstrated
that the number of nuclei with apoptotic morphological
features was increased in Ad-A-p50-infected A549 cells
(Figure 3B). Consistent with this observation, western
blotting demonstrated an increase in cleaved caspase-3 in
Ad-A-p50-infected A549 cells (Figure 3C). These data dem-
onstrate that intracellular delivery of A-p50 induces apop-
tosis. The constitutively high level of nuclear NF-kB
activity in A549 cells has been shown to induce upregulation
of anti-apoptotic genes, such as Bcl-XL (22). Thus, if the
expressed A-p50 aptamer has biological activity in A549
cells, Bcl-XL expression should be diminished by Ad-A-
p50 infection. Indeed, western blotting showed that the Bcl-
XL level was reduced in Ad-A-p50-infected A549 cells
(Figure 3D).
To verify that apoptosis of Ad-A-p50-infected A549 cells
was a speciﬁc effect of the expressed A-p50 aptamer, we
investigated whether a complementary antidote sequence
could inhibit this effect. Transfection of the antidote resulted
in a partial but signiﬁcant reversal of Ad-A-p50 apoptotic
effect, as demonstrated by changes in nuclear morphology
(Figure 3E and F). To explore whether the expressed A-p50
aptamer exhibits biological activity in other cell types, we
evaluated apoptosis in Ad-A-p50-infected 4T1 mouse mam-
mary carcinoma cells. The MTT assay and Hoechst nuclear
staining showed decreased cell viability (Figure 3G) and
increased apoptotic nuclei (Figure 3H) in Ad-A-p50-infected
4T1 cells. Taken together, these in vitro data demonstrate that
the expressed A-p50 RNA aptamer speciﬁcally induces apop-
tosis in cultured tumor cell lines by binding NF-kB p50 and
reversing NF-kB-mediated expression of genes like Bcl-XL.
Although one of the beneﬁts to the expression of RNA
aptamers is in exploring biological pathways such as in the
development and testing of targeted therapeutics, the major
contribution of aptamer lies in the realm of gene therapeutics.
As such, we next determined whether local instillation of Ad-
A-p50 could impair the growth of established tumors. NF-kB
is necessary for tumor cell proliferation, invasion and
angiogenesis (25,26); therefore, inhibitors of NF-kB should
abrogate tumor growth. To examine the effects of Ad-A-
p50 on tumor growth inhibition, A549 tumors were estab-
lished in nude mice. Intra-tumoral injection of Ad-A-p50
resulted in signiﬁcant tumor growth inhibition compared
with Ad-siNT (P < 0.05) beginning 2 weeks after the ﬁrst
virus injection (day 1) (Figure 4A). To investigate the mech-
anisms of Ad-A-p50 effects on tumors in vivo, we performed
immunohistochemistry to analyze markers of proliferation
and apoptosis. Expression of the cell proliferation marker
Ki67 and the cell survival protein Bcl-XL were greatly
reduced in Ad-A-p50-injected tumor tissues compared with
Ad-siNT-infected tumors, while expression of cleaved (act-
ive) caspase-3 was dramatically increased (Figure 4B).
These ﬁndings demonstrate that tumor growth inhibition in
vivo by Ad-A-p50 is due, at least in part, to loss of prolifer-
ative capacity and enhanced apoptosis.
To date, expression of RNA aptamers for in vivo applica-
tions has met with limited success, in part due to interference
from ﬂanking vector sequences. Martell et al. (10) developed
an expression cassette SELEX strategy to randomize ﬂanking
sequences and select for chimeric tRNAs that retained high
afﬁnity for E2F. Despite the apparent success of this
approach, repeated SELEX is technically complex, tedious
and might not be universally effective. Blind et al. (12)
developed a vaccinia virus-based RNA expression system
based on double infection with two recombinant vaccinia vir-
uses encoding T7 polymerase and aptamer, respectively, to
achieve high-level cytoplasmic expression of RNA aptamers
directed against the intracellular domain of the b2 integrin
LFA-1. However, this approach utilized a vector with
50 and 30 ﬂanking stem–loop structures as RNA-stabilizing
motifs, which were also required for correct termination of
the T7 transcripts. It is not clear whether these ﬂanking
Figure 4. A-p50 affects A549 cell survival in vivo through inhibition of
NF-kB-mediated transcriptional activation. (A) Tumor growth delay. Growth
curves are plotted as the mean of tumor volume normalized to tumor size at
the time of infection ± SEM. n ¼ 6–7 animals per group. A significant
difference in tumor volume was observed beginning 2 weeks after the first
virus injection (day 1), which persisted for the remainder of the study,
*P < 0.05. (B) Immunohistochemical analysis of Ki67, activated caspase-3,
and Bcl-XL protein expression. Ad-A-p50 virus-injected tumor tissues show a
decrease in Ki67 protein expression compared with Ad-siNT-injected tumor
tissues (·100 magnification, brownish red nuclear stain), consistent with a
decrease in cell proliferation. Ad-A-p50 virus-injected tumor tissues show a
marked increase in activated caspase-3 levels (·400 magnification, brownish
red nuclear stain) as well as an obvious decrease in Bcl-XL expression (·100
magnification, brownish red stain) compared with Ad-siNT-injected tumor
tissues, consistent with enhanced tumor cell apoptosis.
Nucleic Acids Research, 2006, Vol. 34, No. 12 3583stem–loop structures would be a universally effective strategy
for other aptamers. Furthermore, vaccinia virus is less well
established as a gene delivery vector for in vivo applications,
and the immunogenicity of T7 polymerase will likely limit its
therapeutic utility. An ideal approach to in vivo aptamer
delivery would provide efﬁcient delivery to the target cells
while effecting high-level expression of ‘pure’ aptamer.
Indeed, the RNA aptamer expression vector presented in
this study meets these requirements, and we believe it will
provide a more reliable approach to the delivery of RNA
aptamers for in vitro investigations and in vivo therapy.
One potential limitation to the approach described here is
that transcription by the H1 promoter cannot be precisely
controlled. Recently, two different groups have described
successful regulation of transcription by integrating the bac-
terial tetracycline operon sequence (tetO) into the U6 pro-
moter (27,28), which offers the potential to optimize our
system.
In conclusion, expression of RNA aptamers whose binding
ability and biological activity are retained is feasible utilizing
the expression system described in this study. As very spe-
ciﬁc inhibitors of known proteins can be readily created
through aptamer approaches, this expression system may be
valuable in selective inhibition of intracellular proteins for
in vivo application.
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